Company Profiles

driven by the PitchBook Platform

Acumen Pharmaceuticals

Description

Developer of therapeutics and diagnostics designed to treat Alzheimer's disease and other memory-related disorders. The company's therapeutics and diagnostics develop ACU-193, the lead antibody within the Acumen ADDL-Select program which is fully humanized, IgG2 monoclonal antibody that selectively binds soluble Aβ oligomers and potently blocks their deleterious actions, enabling patients to recover faster from degenerative disorders which result from the aging of brain.

1996

Founded

PRIVATE

Status

11-50

Employees

Later Stage VC

Latest Deal Type

$24.3M

Total Amount Raised

8

Investors

Description

Developer of therapeutics and diagnostics designed to treat Alzheimer's disease and other memory-related disorders. The company's therapeutics and diagnostics develop ACU-193, the lead antibody within the Acumen ADDL-Select program which is fully humanized, IgG2 monoclonal antibody that selectively binds soluble Aβ oligomers and potently blocks their deleterious actions, enabling patients to recover faster from degenerative disorders which result from the aging of brain.

Website:

www.acumenpharm.com

Ownership Status

Privately Held (backing)

Financing Status

Venture Capital-Backed

Primary Industry

Drug Discovery

Primary Office

4435 North First Street Suite 360 Livermore, CA 94551United States +1 (925) 368-8508
    Request a free trial to the PitchBook Platform
    You're viewing a free company profile from the PitchBook Platform. To explore Acumen Pharmaceuticals's full profile, request a free trial.

    Acumen Pharmaceuticals Valuation and Funding

    Request access
    Deal TypeDateAmountRaised to DatePost-ValStatusStage

    Acumen Pharmaceuticals Cap Table

    Stock# of Shares
    Authorized
    Par ValueDividend Rate (%)Original
    Issue Price
    LiquidationLiquidation
    Pref. Multiple
    Conversion
    Price
    % Owned

    Acumen Pharmaceuticals Investors (8)

    Request access
    Investor NameInvestor TypeHoldingInvestor SinceParticipating RoundsBoard
    Seat
    Contact
    Info
    BVF PartnersPE/BuyoutMinority000 0000000 0000
    GDBA InvestmentsVenture CapitalMinority000 0000000 0000
    Glynn Capital ManagementVenture CapitalMinority000 0000000 0000
    Individual InvestorAngel (individual)Minority000 0000000 0000
    NeuroVentures CapitalVenture CapitalMinority000 0000000 0000
    BVF Partners PE/Buyout
    GDBA Investments Venture Capital
    Glynn Capital Management Venture Capital
    Individual Investor Angel (individual)
    NeuroVentures Capital Venture Capital

    Acumen Pharmaceuticals Executive Team (2)

    NameTitleBoard
    Seat
    Contact
    Info
    William Goure Ph.DChief Operating Officer
    Daniel O'ConnellChief Executive Officer, Board Member & President
    William Goure Ph.D Chief Operating Officer
    Daniel O'Connell Chief Executive Officer, Board Member & President

    Acumen Pharmaceuticals Board Members (4)

    NameRepresentingRoleSinceContact
    Info
    Franz Hefti Ph.DAcumen PharmaceuticalsBoard Member000 0000
    Grant Krafft Ph.DSelfCo-Founder, Chief Scientific Adviser and Chairman of the Board of Directors000 0000
    Jeffrey Ives Ph.DSelfBoard Member000 0000
    Mark LampertBVF PartnersPresident & Founder000 0000
    Franz Hefti Ph.D Board Member Acumen Pharmaceuticals
    Grant Krafft Ph.D Co-Founder, Chief Scientific Adviser and Chairman of the Board of Directors Self
    Jeffrey Ives Ph.D Board Member Self
    Mark Lampert President & Founder BVF Partners
    Request full access to PitchBook